391 related articles for article (PubMed ID: 26083891)
1. Neurofibromatosis: part 2--clinical management.
Batista PB; Bertollo EM; Costa Dde S; Eliam L; Cunha KS; Cunha-Melo JR; Darrigo Junior LG; Geller M; Gianordoli-Nascimento IF; Madeira LG; Mendes HM; Miranda DM; Mata-Machado NA; Morato EG; Pavarino ÉC; Pereira LB; Rezende NA; Rodrigues Lde O; Sette JB
Arq Neuropsiquiatr; 2015 Jun; 73(6):531-43. PubMed ID: 26083891
[TBL] [Abstract][Full Text] [Related]
2. Neurofibromatoses: part 1 - diagnosis and differential diagnosis.
Rodrigues LO; Batista PB; Goloni-Bertollo EM; de Souza-Costa D; Eliam L; Eliam M; Cunha KS; Darrigo-Junior LG; Ferraz-Filho JR; Geller M; Gianordoli-Nascimento IF; Madeira LG; Malloy-Diniz LF; Mendes HM; de Miranda DM; Pavarino EC; Baptista-Pereira L; Rezende NA; Rodrigues Lde O; da Silva CM; de Souza JF; de Souza ML; Stangherlin A; Valadares ER; Vidigal PV
Arq Neuropsiquiatr; 2014 Mar; 72(3):241-50. PubMed ID: 24676443
[TBL] [Abstract][Full Text] [Related]
3. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.
Merker VL; Dai A; Radtke HB; Knight P; Jordan JT; Plotkin SR
BMC Health Serv Res; 2018 Aug; 18(1):668. PubMed ID: 30157837
[TBL] [Abstract][Full Text] [Related]
4. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
[TBL] [Abstract][Full Text] [Related]
5. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.
Vranceanu AM; Merker VL; Park E; Plotkin SR
J Neurooncol; 2013 Sep; 114(3):257-62. PubMed ID: 23817811
[TBL] [Abstract][Full Text] [Related]
6. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
Fisher MJ; Belzberg AJ; de Blank P; De Raedt T; Elefteriou F; Ferner RE; Giovannini M; Harris GJ; Kalamarides M; Karajannis MA; Kim A; Lázaro C; Le LQ; Li W; Listernick R; Martin S; Morrison H; Pasmant E; Ratner N; Schorry E; Ullrich NJ; Viskochil D; Weiss B; Widemann BC; Zhu Y; Bakker A; Serra E
Am J Med Genet A; 2018 May; 176(5):1258-1269. PubMed ID: 29681099
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.
Blakeley JO; Plotkin SR
Neuro Oncol; 2016 May; 18(5):624-38. PubMed ID: 26851632
[TBL] [Abstract][Full Text] [Related]
8. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.
Blakeley JO; Bakker A; Barker A; Clapp W; Ferner R; Fisher MJ; Giovannini M; Gutmann DH; Karajannis MA; Kissil JL; Legius E; Lloyd AC; Packer RJ; Ramesh V; Riccardi VM; Stevenson DA; Ullrich NJ; Upadhyaya M; Stemmer-Rachamimov A
Am J Med Genet A; 2017 Jun; 173(6):1714-1721. PubMed ID: 28436162
[TBL] [Abstract][Full Text] [Related]
9. From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.
Ferner RE; Bakker A; Elgersma Y; Evans DGR; Giovannini M; Legius E; Lloyd A; Messiaen LM; Plotkin S; Reilly KM; Schindeler A; Smith MJ; Ullrich NJ; Widemann B; Sherman LS
Am J Med Genet A; 2019 Jun; 179(6):1098-1106. PubMed ID: 30908866
[TBL] [Abstract][Full Text] [Related]
10. Schwannomatosis: the overlooked neurofibromatosis?
Koontz NA; Wiens AL; Agarwal A; Hingtgen CM; Emerson RE; Mosier KM
AJR Am J Roentgenol; 2013 Jun; 200(6):W646-53. PubMed ID: 23701098
[TBL] [Abstract][Full Text] [Related]
11. [Polyneuropathy associated with neurofibromatosis].
Drouet A; Créange A
Rev Neurol (Paris); 2005 Mar; 161(3):275-83. PubMed ID: 15800448
[TBL] [Abstract][Full Text] [Related]
12. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1.
Evans DGR; Salvador H; Chang VY; Erez A; Voss SD; Schneider KW; Scott HS; Plon SE; Tabori U
Clin Cancer Res; 2017 Jun; 23(12):e46-e53. PubMed ID: 28620004
[TBL] [Abstract][Full Text] [Related]
13. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
Tamura R
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072574
[TBL] [Abstract][Full Text] [Related]
14. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
[TBL] [Abstract][Full Text] [Related]
15. Advances in the treatment of neurofibromatosis-associated tumours.
Lin AL; Gutmann DH
Nat Rev Clin Oncol; 2013 Nov; 10(11):616-24. PubMed ID: 23939548
[TBL] [Abstract][Full Text] [Related]
16. The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study.
Vranceanu AM; Merker VL; Plotkin SR; Park ER
J Neurooncol; 2014 Oct; 120(1):103-9. PubMed ID: 25022450
[TBL] [Abstract][Full Text] [Related]
17. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.
Plotkin SR; Bredella MA; Cai W; Kassarjian A; Harris GJ; Esparza S; Merker VL; Munn LL; Muzikansky A; Askenazi M; Nguyen R; Wenzel R; Mautner VF
PLoS One; 2012; 7(4):e35711. PubMed ID: 22558206
[TBL] [Abstract][Full Text] [Related]
18. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.
Merker VL; Bredella MA; Cai W; Kassarjian A; Harris GJ; Muzikansky A; Nguyen R; Mautner VF; Plotkin SR
Am J Med Genet A; 2014 Jun; 164A(6):1431-7. PubMed ID: 24664633
[TBL] [Abstract][Full Text] [Related]
19. Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online survey.
Wolters PL; Ghriwati NA; Baker M; Martin S; Berg D; Erickson G; Franklin B; Merker VL; Oberlander B; Reeve S; Rohl C; Rosser T; Vranceanu AM
Clin Trials; 2024 Feb; 21(1):73-84. PubMed ID: 37962219
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review of Recent and Ongoing Clinical Trials in Patients With the Neurofibromatoses.
Acar S; Nieblas-Bedolla E; Armstrong AE; Hirbe AC
Pediatr Neurol; 2022 Sep; 134():1-6. PubMed ID: 35759947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]